BioPharmSignal logoBioPharmSignal

Biotech News

electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

electroCore (ECOR)electroCoreCommercial

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place on Wednesday, November 11, 2026, at The Westin New York Grand Central in New York City.

Related news

ECORelectroCore2026-10-21 12:00 EST

electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub

ECORelectroCore2026-09-10 12:00 EST

electroCore to Participate at H.C. Wainwright Global Investment Conference

SNYSanofi2026-10-12 16:05 EST

Sanofi: Information concerning the total number of voting rights and shares – September 2026

XERSXeris Pharmaceuticals2026-10-15 12:00 EST

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

TNXPTonix Pharmaceuticals2026-10-15 11:00 EST

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

TNXPTonix Pharmaceuticals2026-09-22 11:00 EST

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

XERSXeris Pharmaceuticals2026-11-02 13:00 EST

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

ALKSAlkermes plc2026-09-10 11:00 EST

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

MNOVMediciNova2026-10-06 10:00 EST

MediciNova to Participate in the Maxim Growth Summit

AXSMAxsome2026-11-03 12:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

View all latest news

electroCore

Noninvasive Neuromodulation electroCore develops handheld bioelectronic devices that stimulate the vagus nerve without surgery. Its products are used across prescription and consumer channels. gammaCore gammaCore is a prescription noninvasive vagus-nerve-stimulation device used for headache disorders. A major commercial channel is the...

Recent company news

ECORelectroCore2026-11-05 13:00 EST

electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

ECORelectroCore2026-10-29 12:00 EST

electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026

ECORelectroCore2026-10-28 12:00 EST

electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

ECORelectroCore2026-10-27 12:00 EST

fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning

ECORelectroCore2026-10-21 12:00 EST

electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub

Stock data

Close
8.80 USD
Market cap
78.39M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States